DEA licenses Pharmatek for controlled substance analysis

- Last updated on GMT

Pharmatek Laboratories has received US DEA approval for the analysis of Schedule I to IV controlled substances.

The US Drug Enforcement Agency (DEA) license allows Pharmatek to perform analytical and stability testing of controlled-substance drug products in its non-potent and highly-potent plants. Pharmatek already had a license to develop and manufacture Schedule IV and V products.

"Receipt of this additional registration from the DEA…further validates our facility design, security systems, and procedures for analysis, handling, storage and disposal of controlled substances​", said Jeffrey Bibbs, CEO and chief scientific officer at Pharmatek.

Related topics: Contract Manufacturing

Related news